buparlisib(一种泛I类PI3K抑制剂)联合紫杉醇治疗HER2阴性晚期乳腺癌的随机适应性II/III期研究(BELLE-4)
BELLE-4研究将416例既往未接受过晚期化疗的HER2阴性局部晚期或转移性乳腺癌患者按1:1随机分配至buparlisib或安慰剂联合紫杉醇组。适应性中期分析显示,在全人群和PI3K通路激活人群中,buparlisib组的中位无进展生存期(PFS)均未优于安慰剂组。研究因无效而终止于II期。
要点
- buparlisib联合紫杉醇未改善全人群或PI3K通路激活人群的PFS。
- 全人群中位PFS:buparlisib组8.0个月 vs 安慰剂组9.2个月(HR 1.18)。
- PI3K通路激活人群中位PFS:buparlisib组9.1个月 vs 安慰剂组9.2个月(HR 1.17)。
核心结论
- 在紫杉醇基础上加用buparlisib未能改善全人群或PI3K通路激活人群的PFS,研究因无效在II期结束时终止。
研究设计与样本
- BELLE-4是一项1:1随机、双盲、安慰剂对照的适应性II/III期研究。
- 研究对象为既往未接受过晚期化疗的HER2阴性局部晚期或转移性乳腺癌女性患者。
- 患者按PI3K通路激活状态和激素受体状态分层,随机接受buparlisib或安慰剂联合紫杉醇治疗。
- 主要终点为全人群和PI3K通路激活人群的PFS。
- 计划在II期部分全人群出现至少125例PFS事件后进行适应性中期分析,以决定是否进入III期或因无效终止。
主要发现
- 截至2014年8月,共416例患者被随机分配至buparlisib组(207例)或安慰剂组(209例)接受紫杉醇治疗。
- 全人群中位PFS:buparlisib组8.0个月 vs 安慰剂组9.2个月(HR 1.18)。
- PI3K通路激活人群中位PFS:buparlisib组9.1个月 vs 安慰剂组9.2个月(HR 1.17)。
- 研究在全人群和PI3K通路激活人群中均达到方案预设的无效标准,未启动III期。
- buparlisib组的中位研究治疗暴露时间为3.5个月,安慰剂组为4.6个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Phosphatidylinositol 3-kinase (PI3K) pathway activation in preclinical models of breast cancer is associated with tumor growth and resistance to anticancer therapies, including paclitaxel. Effects of the pan-Class I PI3K inhibitor buparlisib (BKM120) appear synergistic with paclitaxel in preclinical and clinical models. PATIENTS AND METHODS: BELLE-4 was a 1:1 randomized, double-blind, placebo-controlled, adaptive phase II/III study investigating the combination of buparlisib or placebo with paclitaxel in women with human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with no prior chemotherapy for advanced disease. Patients were stratified by PI3K pathway activation and hormone receptor status. The primary endpoint was progression-free survival (PFS) in the full and PI3K pathway-activated populations. An adaptive interim analysis was planned following the phase II part of the study, after ≥125 PFS events had occurred in the full population, to decide whether the study would enter phase III (in the full or PI3K pathway-activated population) or be stopped for futility. RESULTS: As of August 2014, 416 patients were randomized to receive buparlisib (207) or placebo (209) with paclitaxel. At adaptive interim analysis, there was no improvement in PFS with buparlisib versus placebo in the full (median PFS 8.0 versus 9.2 months, hazard ratio [HR] 1.18), or PI3K pathway-activated population (median PFS 9.1 versus 9.2 months, HR 1.17). The study met protocol-specified criteria for futility in both populations, and phase III was not initiated. Median duration of study treatment exposure was 3.5 months in the buparlisib arm versus 4.6 months in the placebo arm. The most frequent adverse events with buparlisib plus paclitaxel (≥40% of patients) were diarrhea, alopecia, rash, nausea, and hyperglycemia. CONCLUSIONS: Addition of buparlisib to paclitaxel did not improve PFS in the full or PI3K pathway-activated study population. Consequently, the trial was stopped for futility at the end of phase II.
引用
- Martín M, Chan A, Dirix L, et al. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol. 2017. PMID: 27803006. doi:10.1093/annonc/mdw562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。